Scarica l'app Stockscreener
30.35
3.94%
1.15
Dopo l'orario di chiusura:
29.05
-1.30
-4.28%
Parabilis Medicines Inc Borsa (PBLS) Ultime notizie
Leerink Partners Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $40 - Moomoo
Leerink initiates Parabilis Medicines stock with Outperform rating By Investing.com - Investing.com South Africa
The biggest biotech funding rounds in June 2026 - Labiotech.eu
PBLS Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway - TipRanks
Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target - TipRanks
BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Guggenheim initiates Parabilis Medicines stock with buy rating - Investing.com
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Large VC financings improve in H1 2026 - BioWorld News
Nasdaq Delivers the Strongest First Half in U.S. Exchange History as Public Markets Momentum Builds - Moomoo
Mass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pace - The Business Journals
Insider Stock Purchases: June 29, 2026 - Quiver Quantitative
[Form 4] Parabilis Medicines, Inc. Insider Trading Activity - Stock Titan
Parabilis Medicines (PBLS) holder reports 527,070-share Series F position - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
PBLS|Parabilis Medicines Ord Shs|Price:28.800|Chg%:2.44 - TradingKey
Price to earnings forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Price to book forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
PBLS: Parabilis Medicines, Inc.12 Month EPS - Zacks Investment Research
Price to sales forward of Parabilis Medicines, Inc. – BOATS:PBLS - TradingView
Parabilis Medicines (PBLS) Insider Trading Activity 2026 - MarketBeat
Enterprise value to EBIT forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Parabilis Medicines (PBLS) Stock Trends and Sentiment 2026 - MarketBeat
Parabilis Medicines, Inc. (PBLS) Book Value (Per Share) - Zacks Investment Research
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Total operating expenses of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? - The Globe and Mail
PBLSParabilis Medicines Inc Forecast, Target Price - Finviz
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
RA Capital Management Discloses Investment at Parabilis Medicines with 23.8% Stake - TradingView
[SCHEDULE 13D] Parabilis Medicines, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
PBLS SEC FilingsPARABILIS MEDICINES INC 10-K, 10-Q, 8-K Forms - Stock Titan
PBLS Technical Analysis & Stock Price Forecast - Intellectia AI
PBLS PE Ratio & Valuation, Is PBLS Overvalued - Intellectia AI
PBLS | Parabilis Medicines, Inc. Common Institutional Ownership - Quiver Quantitative
Apothecary Capital, tied to Parabilis (PBLS) director, buys 17,500 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Parabilis Medicines stock jumps on insider buying activity By Investing.com - Investing.com Nigeria
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines stock jumps on insider buying activity - Investing.com
PBLS | Parabilis Medicines, Inc. Common Insider Trading - Quiver Quantitative
RA Capital funds lift Parabilis Medicines (PBLS) common equity exposure - Stock Titan
Parabilis Medicines (PBLS) director converts preferred stock into common around IPO - Stock Titan
Parabilis (PBLS) director-linked LLC makes open-market buy of 12,500 shares - Stock Titan
Parabilis Medicines (PBLS) director converts Series F preferred into common in IPO - Stock Titan
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline - Yahoo Finance
PBLS : Parabilis Medicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Regeneron-backed Parabilis surges after record-setting IPO - MSN
Parabilis Medicines (PBLS) Stock Chart and Price History 2026 - MarketBeat
PBLS News Today | Why did Parabilis Medicines stock go up today? - MarketBeat
Parabilis Medicines prices upsized IPO at $19 per share - MSN
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):